Compare Five9 Inc (FIVN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Recursion Pharmaceuticals Inc — how do they compare? Five9 Inc trades at $36.22 (market cap $2.63B), while Recursion Pharmaceuticals Inc trades at $4.35 (market cap $2.14B). The key difference: Five9 Inc is the larger of the two by market cap, and Five9 Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| FIVN | RXRX | |
|---|---|---|
Market Cap | $2.63B | $2.14B |
Volume | 1,864,393 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $38.65 | $6.79 |
52-Week Low | $13.61 | $2.84 |
Typical Hold Time | 72 Days | 23 Days |
Enterprise Value | $2.78B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $35.10, up 3.91% with strong technical momentum near recent highs. The company shows accelerating revenue growth, reaching $1.15B in 2025 with improving profitability (net margin 4.94%). Recent quarters have consistently beaten EPS estimates, while AI revenue surged 78% YoY to $39M in Q2 2026. Analyst sentiment remains bullish with 61% buy ratings and a $34 consensus target.
Outlook remains positive driven by AI contact center adoption and subscription growth, though high valuation multiples (P/E 51.7) and insider selling present near-term risks. The stock's technical setup suggests continued upside if it maintains above $34 support, but investors should monitor debt levels and competitive pressures in the CCaaS space.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
